UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Autophagy as a therapeutic target in cancer

Cancer biology & therapy, 2011-01, Vol.11 (2), p.157-168

2011

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Link zum Volltext

Verfügbarkeit prüfen

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.143-143, Article 143

2019

Link zum Volltext

Verfügbarkeit prüfen

Molecular pathways: autophagy in cancer--a matter of timing and context

Clinical cancer research, 2015-02, Vol.21 (3), p.498-504

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2804-2811

2018

Link zum Volltext

Verfügbarkeit prüfen

Autophagy in malignant transformation and cancer progression

The EMBO journal, 2015-04, Vol.34 (7), p.856-880

2015

Link zum Volltext

Verfügbarkeit prüfen

Role of Autophagy in Breast Cancer

Autophagy, 2007-11, Vol.3 (6), p.610-613

2007

Link zum Volltext

Verfügbarkeit prüfen

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Genes & development, 2011-03, Vol.25 (5), p.460-470

2011

Link zum Volltext

Verfügbarkeit prüfen

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Genes & development, 2007-07, Vol.21 (13), p.1621-1635

2007

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Link zum Volltext

Verfügbarkeit prüfen

Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation

World journal of gastrointestinal oncology, 2014-03, Vol.6 (3), p.74-82

2014

Link zum Volltext

Verfügbarkeit prüfen

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Autophagy, 2008-07, Vol.4 (5), p.731-733

Karantza, Vassiliki

2008

Link zum Volltext

Verfügbarkeit prüfen

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

The journal of pathology. Clinical research, 2024-05, Vol.10 (3), p.e12371-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A364-A364

2021

Link zum Volltext

Verfügbarkeit prüfen

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

Molecular & cellular oncology, 2015-07, Vol.2 (3), p.e975035-e975035

2015

Link zum Volltext

Verfügbarkeit prüfen

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (11), p.4105-4115

2008

Link zum Volltext

Verfügbarkeit prüfen

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567

2022

Link zum Volltext

Verfügbarkeit prüfen

The interplay between autophagy and ROS in tumorigenesis

Frontiers in oncology, 2012, Vol.2, p.171

2012

Link zum Volltext

Verfügbarkeit prüfen

Role and regulation of autophagy in cancer

Biochimica et biophysica acta, 2009-09, Vol.1793 (9), p.1516-1523

2009

Link zum Volltext

Verfügbarkeit prüfen

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity

Autophagy, 2014-11, Vol.10 (11), p.2036-2052

2014

Link zum Volltext

Verfügbarkeit prüfen

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Molecular cancer research, 2009-09, Vol.7 (9), p.1487-1496

2009

Link zum Volltext

Verfügbarkeit prüfen

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (24), p.5427-5434

2020

Link zum Volltext

Verfügbarkeit prüfen

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 59

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

KollektionEZB Free E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(58)
Berichte
(1)

Sprache

Englisch
(59)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Autophagy as a therapeutic target in cancer

Pembrolizumab for Early Triple-Negative Breast Cancer

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Molecular pathways: autophagy in cancer--a matter of timing and context

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Autophagy in malignant transformation and cancer progression

Role of Autophagy in Breast Cancer

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

The interplay between autophagy and ROS in tumorigenesis

Role and regulation of autophagy in cancer

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Aktive Filter

Suchergebnisse filtern